Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Commentary on plateau in lupus nephritis trials and path to precision medicine
New lupus drugs hit a ceiling where kidney healing stops improving
This commentary reviews 200 interventional pharmacological trials in lupus nephritis. The authors note a persistent ceiling effect with comp…
Kidney healing in lupus patients using new drugs often stops improving after reaching a 40 to 50 percent success rate, limiting how much bet…
Complement inhibitors and FcRn blockers improve outcomes in AChR-Ab+ generalized myasthenia gravis
New Drugs Double Your Chance of Getting Better
A meta-analysis of 739 adults in RCTs and 588 in OLEs with acetylcholine receptor antibody-positive generalized myasthenia gravis found that…
New drugs for generalized myasthenia gravis double the odds of meaningful improvement while reducing the need for rescue therapy and severe …